Your Trusted Brand for Over 35 Years

Life Extension Magazine

<< Back to June 2014

Maximizing Omega-3 Health Benefits

June 2014

By S.R. Knowlton

Do You Know Your Omega Score?

Life Extension® readers know that omega-3 fatty acids combat cardiovascular disease through a host of interrelated mechanisms, including the suppression of pro-inflammatory cytokines, and reduction of triglycerides. Less known is the importance of a novel analytic technology to assess how much omega-3 is in one’s whole blood, serum, and red blood cells.87-92

This low-cost, in-home, personalized assessment, called the Omega Score provides a clear picture of the percentage of EPA/DHA omega-3 fatty acids in your blood. The benefits of knowing this information can be the difference between life and death, as the ratio of omega-3 to omega-6 fatty acids in blood and cell membranes strongly influences cardiovascular disease risk factors.87,93

The test is based on the groundbreaking work of a team of Harvard researchers. They found that people with total omega-3 levels between 6.1 and 10.2% in their blood had a compelling 90% lower risk of sudden cardiac death compared with those whose omega-3s were 2.1 to 4.3% or less of their total fatty acids.94 People with omega-3 levels between 4.3 and 5.2% attained some benefit, with a 48% reduction in risk, while those whose scores were between 5.2 and 6.1% had an 81% risk reduction.94 Knowing your omega-3 levels via the Omega Score enables you to establish several key indices of cardiovascular risk, including risk of sudden cardiac death,95 risk for developing heart disease,95,96 and risk of fatal ischemic heart disease.97 This crucial information can then be used to create an omega-3 supplement regime with the appropriate amount of omega-3s to attain healthy blood levels that may prevent a lethal cardiac event.

Additionally, the Omega Score is one of the only tests that can check the level of a special omega-7 fatty acid called palmitoleic acid that has recently been connected with reduced risk of metabolic syndrome, improving insulin sensitivity, and lowering triglycerides, glucose, and CRP levels. This omega-7 fat also has a profound effect on the body’s response to energy intake and fat intake and it helps suppress production of new fat.98,99

For added convenience, the Omega Score test does not require a trip to a blood-drawing lab. You can simply obtain the specimen yourself by a finger stick at home, and then send the sample to the lab for testing. Your results will be sent to you through the mail, with graphic illustrations for easier understanding.

To order the Omega Score test, call 1-800-208-3444. You will receive a test kit in the mail. All you have to do is collect a sample and return it in the pre-paid envelope. You will receive your test results by mail.

Summary

Growing evidence suggests that fish oil omega-3s are complemented by those from krill oil, which occur naturally in a form that can be readily taken up by cell membranes.

Fish oil and krill oil have now been shown to provide superior neuroprotection, protecting vital brain areas from age-related shrinkage and dysfunction. Such measures may prevent memory loss, dementia, and even depression.

Fish and krill oils combined also optimize cardiovascular health to lower blood lipids, reduce the risk of arrhythmias, and prevent heart attacks and the damage they cause. Similarly, the marine oils lower risk for obesity, diabetes, and metabolic syndrome, which in turn can lower chances of developing diseases from cancer to stroke. And now there’s evidence that these oils can ameliorate osteoporosis and painful arthritis.

Thus, both fish oil and krill oil offer secure, complementary coverage to safeguard the health of our aging bodies.

If you have any questions on the scientific content of this article, please call a Life Extension® Wellness Specialist at 1-866-864-3027.

References

  1. Available at: http://www.jlr.org/content/40/10/1867.long#xref-ref-23-1.Accessed March 25, 2014.
  2. Available at: http://www.jlr.org/content/40/10/1867.long#xref-ref-23-1. Accessed March 25, 2014.
  3. Ramprasath VR, Eyal I, Zchut S, Jones PJ. Enhanced increase of omega-3 index in healthy individuals with response to 4-week n-3 fatty acid supplementation from krill oil versus fish oil. Lipids Health Dis. 2013;12(1):178.
  4. Ulven SM, Kirkhus B, Lamglait A, et al. Metabolic effects of krill oil are essentially similar to those of fish oil but at lower dose of EPA and DHA, in healthy volunteers. Lipids. 2011 Jan;46(1):37-46.
  5. Available at: http://www.jlr.org/content/40/10/1867.long#xref-ref-23-1. Accessed March 25, 2014.
  6. Available at: http://www.jlr.org/content/40/10/1867.long#xref-ref-23-1. Accessed March 25, 2014.
  7. Available at: http://www.jlr.org/content/40/10/1867.long#xref-ref-23-1. Accessed March 25, 2014.
  8. Innis S M. Plasma and red blood cell fatty acid values as indexes of essential fatty acids in the developing organs of infants fed with milk or formulas. J Pediatr. 1992;120: S78–S86.
  9. Thies F, Pillon C, Moliere P, Lagarde M, Lecerf J. Preferential incorporation of sn-2 lysoPC DHA over unesterified DHA in young rat brain. Am J Physiol. 1994;36:R1273–9.
  10. Vaisman N, Kaysar N, Zaruk-Adasha Y, et al. Correlation between changes in blood fatty acid composition and visual sustained attention performance in children with inattention: effect of dietary n-3 fatty acids containing phospholipids. Am J Clin Nutr. 2008;87:1170–80.
  11. Kidd PM. Omega-3 DHA and EPA for cognition, behavior, and mood: clinical findings and structural-functional synergies with cell membrane phospholipids. Altern Med Rev. 2007 Sep;12(3):207-27.
  12. Fotuhi M, Do D, Jack C. Modifiable factors that alter the size of the hippocampus with ageing. Nat Rev Neurol. 2012 Apr;8(4):189-202.
  13. Tsopelas C, Stewart R, Savva GM, et al. Neuropathological correlates of late-life depression in older people. Br J Psychiatry. 2011 Feb;198(2):109-14.
  14. Zahodne LB, Gongvatana A, Cohen RA, Ott BR, Tremont G. Are apathy and depression independently associated with longitudinal trajectories of cortical atrophy in mild cognitive impairment? Am J Geriatr Psychiatry. 2013 Nov;21(11):1098-106.
  15. Titova OE, Sjogren P, Brooks SJ, et al. Dietary intake of eicosapentaenoic and docosahexaenoic acids is linked to gray matter volume and cognitive function in elderly. Age (Dordr). 2013 Aug;35(4):1495-505.
  16. Bowman GL, Silbert LC, Howieson D, et al. Nutrient biomarker patterns, cognitive function, and MRI measures of brain aging. Neurology. 2012 Jan 24;78(4):241-9.
  17. Albanese E, Dangour AD, Uauy R, et al. Dietary fish and meat intake and dementia in Latin America, China, and India: a 10/66 Dementia Research Group population-based study. Am J Clin Nutr. 2009 Aug;90(2):392-400.
  18. Walhovd KB, Storsve AB, Westlye LT, Drevon CA, Fjell AM. Blood markers of fatty acids and vitamin D, cardiovascular measures, body mass index, and physical activity relate to longitudinal cortical thinning in normal aging. Neurobiol Aging. 2013 Nov 21.
  19. Blondeau N, Pétrault O, Manta S, Giordanengo V, Gounon P, Bordet R, Lazdunski M, Heurteaux C. Polyunsaturated fatty acids are cerebral vasodilators via the TREK-1 potassium channel. Circ Res. 2007 Jul 20;101(2):176-84.
  20. Sinn N., Howe P.R.C. Mental health benefits of omega-3 fatty acids may be mediated by improvements in cerebral vascular function. Biosci Hypotheses. 2008;1:103–8.
  21. Tan ZS, Harris WS, Beiser AS, et al. Red blood cell omega-3 fatty acid levels and markers of accelerated brain aging. Neurology. 2012 Feb 28;78(9):658-64.
  22. Pottala JV, Yaffe K, Robinson JG, Espeland MA, Wallace R, Harris WS. Higher RBC EPA + DHA corresponds with larger total brain and hippocampal volumes: WHIMS-MRI Study. Neurology. 2014 Jan 22.
  23. Kang JX, Gleason ED. Omega-3 Fatty acids and hippocampal neurogenesis in depression. CNS Neurol Disord Drug Targets. 2013 Jun;12(4):460-5.
  24. Perez MA, Terreros G, Dagnino-Subiabre A. Long-term omega-3 fatty acid supplementation induces anti-stress effects and improves learning in rats. Behav Brain Funct. 2013 Jun 14;9(1):25.
  25. Jia D, Heng LJ, Yang RH, Gao GD. Fish oil improves learning impairments of diabetic rats by blocking PI3K/AKT/nuclear factor-kappaB-mediated inflammatory pathways. Neuroscience. 2013 Nov 16.
  26. Freund-Levi Y, Eriksdotter-Jonhagen M, Cederholm T, et al. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch Neurol. 2006 Oct;63(10):1402-8.
  27. Thies F, Pillon C, Moliere P, Lagarde M, Lecerf J. Preferential incorporation of sn-2 lysoPC DHA over unesterified DHA in young rat brain. Am J Physiol. 1994 Nov;36: R1273–9.
  28. Park HJ, Shim HS, Kim KS, et al. Enhanced learning and memory of normal young rats by repeated oral administration of Krill Phosphatidylserine. Nutr Neurosci. 2013 Mar;16(2):47-53.
  29. Wibrand K, Berge K, Messaoudi M, et al. Enhanced cognitive function and antidepressant-like effects after krill oil supplementation in rats. Lipids Health Dis. 2013;12:6.
  30. Konagai C, Yanagimoto K, Hayamizu K, Han L, Tsuji T, Koga Y. Effects of krill oil containing n-3 polyunsaturated fatty acids in phospholipid form on human brain function: a randomized controlled trial in healthy elderly volunteers. Clin Interv Aging. 2013;8:1247-57.
  31. Hayakawa S, Yoshikawa D, Ishii H, et al. Association of plasma omega-3 to omega-6 polyunsaturated fatty acid ratio with complexity of coronary artery lesion. Intern Med. 2012;51(9):1009-14.
  32. Huang T, Shou T, Cai N, Wahlqvist ML, Li D. Associations of plasma n-3 polyunsaturated fatty acids with blood pressure and cardiovascular risk factors among Chinese. Int J Food Sci Nutr. 2012 Sep;63(6):667-73.
  33. Wu JH, Lemaitre RN, King IB, et al. Association of plasma phospholipid long-chain omega-3 fatty acids with incident atrial fibrillation in older adults: the cardiovascular health study. Circulation. 2012 Mar 6;125(9):1084-93.
  34. Hara M, Sakata Y, Nakatani D, et al. Low levels of serum n-3 polyunsaturated fatty acids are associated with worse heart failure-free survival in patients after acute myocardial infarction. Circ J. 2013;77(1):153-62.
  35. Jung SB, Kwon SK, Kwon M, et al. Docosahexaenoic acid improves vascular function via up-regulation of SIRT1 expression in endothelial cells. Biochem Biophys Res Commun. 2013 Jul 19;437(1):114-9.
  36. Lluis L, Taltavull N, Munoz-Cortes M, et al. Protective effect of the omega-3 polyunsaturated fatty acids: Eicosapentaenoic acid/Docosahexaenoic acid 1:1 ratio on cardiovascular disease risk markers in rats. Lipids Health Dis. 2013;12(1):140.
  37. Turgeon J, Dussault S, Maingrette F, et al. Fish oil-enriched diet protects against ischemia by improving angiogenesis, endothelial progenitor cell function and postnatal neovascularization. Atherosclerosis. 2013 Aug;229(2):295-303.
  38. Younan SM, Rashed LA, Abd El Aziz OM. Cardioprotective modulation of cardiac adiponectin and adiponectin receptors by omega-3 in the high-fat fed rats. Chin J Physiol. 2013 Apr 30;56(2):65-76.
  39. Hoshi T, Wissuwa B, Tian Y, et al. Omega-3 fatty acids lower blood pressure by directly activating large-conductance Ca(2)(+)-dependent K(+) channels. Proc Natl Acad Sci USA. 2013 Mar 19;110(12):4816-21.
  40. Bays HE, Ballantyne CM, Kastelein JJ, Isaacsohn JL, Braeckman RA, Soni PN. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial). Am J Cardiol. 2011 Sep 1;108(5):682-90.
  41. Jacobson TA. A new pure omega-3 eicosapentaenoic acid ethyl ester (AMR101) for the management of hypertriglyceridemia: the MARINE trial. Expert Rev Cardiovasc Ther. 2012 Jun;10(6):687-95.
  42. Tatsuno I, Saito Y, Kudou K, Ootake J. Efficacy and safety of TAK-085 compared with eicosapentaenoic acid in Japanese subjects with hypertriglyceridemia undergoing lifestyle modification: the omega-3 fatty acids randomized double-blind (ORD) study. J Clin Lipidol. 2013 May-Jun;7(3):199-207.
  43. Ballantyne CM, Bays HE, Kastelein JJ, et al. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). Am J Cardiol. 2012 Oct 1;110(7):984-92.
  44. Ballantyne CM, Braeckman RA, Soni PN. Icosapent ethyl for the treatment of hypertriglyceridemia. Expert Opin Pharmacother. 2013 Jul;14(10):1409-16.
  45. Bays HE, Ballantyne CM, Braeckman RA, Stirtan WG, Soni PN. A new pure omega-3 eicosapentaenoic acid ethyl ester (AMR101) for the management of hypertriglyceridemia: the MARINE trial. Am J Cardiovasc Drugs. 2013 Feb;13(1):37-46.
  46. Bozcali E, Babalik E, Himmetoglu S, Mihmanli I, Toprak S. omega-3 fatty acid treatment in cardiac syndrome X: a double-blind, randomized, placebo-controlled clinical study. Coron Artery Dis. 2013 Jun;24(4):328-33.
  47. McEwen BJ, Morel-Kopp MC, Chen W, Tofler GH, Ward CM. Effects of omega-3 polyunsaturated fatty acids on platelet function in healthy subjects and subjects with cardiovascular disease. Semin Thromb Hemost. 2013 Feb;39(1):25-32.
  48. Wong AT, Chan DC, Barrett PH, Adams LA, Watts GF. Supplementation with n3 fatty acid ethyl esters increases large and small artery elasticity in obese adults on a weight loss diet. J Nutr. 2013 Apr;143(4):437-41.
  49. Available at: http://www.jlr.org/content/40/10/1867.long#ref-17. Accessed March 25, 2014.
  50. Batetta B, Griinari M, Carta G, et al. Endocannabinoids may mediate the ability of (n-3) fatty acids to reduce ectopic fat and inflammatory mediators in obese Zucker rats. J Nutr. 2009 Aug;139(8):1495-501.
  51. Flores A, Maldonado R, Berrendero F. Cannabinoid-hypocretin cross-talk in the central nervous system: what we know so far. Front Neurosci. 2013;7:256.
  52. Karatsoreos IN, Thaler JP, Borgland SL, Champagne FA, Hurd YL, Hill MN. Food for thought: hormonal, experiential, and neural influences on feeding and obesity. J Neurosci. 2013 Nov 6;33(45):17610-6.
  53. Piscitelli F, Carta G, Bisogno T, et al. Effect of dietary krill oil supplementation on the endocannabinoidome of metabolically relevant tissues from high-fat-fed mice. Nutr Metab (Lond). 2011;8(1):51.
  54. Fosshaug LE, Berge RK, Beitnes JO, et al. Krill oil attenuates left ventricular dilatation after myocardial infarction in rats. Lipids Health Dis. 2011;10:245.
  55. Ebrahimi M, Ghayour-Mobarhan M, Rezaiean S, et al. Omega-3 fatty acid supplements improve the cardiovascular risk profile of subjects with metabolic syndrome, including markers of inflammation and auto-immunity. Acta Cardiol. 2009 Jun;64(3):321-7.
  56. Ludwig T, Worsch S, Heikenwalder M, Daniel H, Hauner H, Bader BL. Metabolic and immunomodulatory effects of n-3 fatty acids are different in mesenteric and epididymal adipose tissue of diet-induced obese mice. Am J Physiol Endocrinol Metab. 2013 Jun 1;304(11):E1140-56.
  57. Derosa G, Cicero AF, Fogari E, et al. Effects of n-3 PUFAs on postprandial variation of metalloproteinases, and inflammatory and insulin resistance parameters in dyslipidemic patients: evaluation with euglycemic clamp and oral fat load. J Clin Lipidol. 2012 Nov-Dec;6(6):553-64.
  58. Rafraf M, Mohammadi E, Asghari-Jafarabadi M, Farzadi L. Omega-3 fatty acids improve glucose metabolism without effects on obesity values and serum visfatin levels in women with polycystic ovary syndrome. J Am Coll Nutr. 2012 Oct;31(5):361-8.
  59. Lamping KG, Nuno DW, Coppey LJ, et al. Modification of high saturated fat diet with n-3 polyunsaturated fat improves glucose intolerance and vascular dysfunction. Diabetes Obes Metab. 2013 Feb;15(2):144-52.
  60. Lanza IR, Blachnio-Zabielska A, Johnson ML, et al. Influence of fish oil on skeletal muscle mitochondrial energetics and lipid metabolites during high-fat diet. Am J Physiol Endocrinol Metab. 2013 Jun 15;304(12):E1391-403.
  61. Spencer M, Finlin BS, Unal R, et al. Omega-3 fatty acids reduce adipose tissue macrophages in human subjects with insulin resistance. Diabetes. 2013 May;62(5):1709-17.
  62. Yan Y, Jiang W, Spinetti T, et al. Omega-3 fatty acids prevent inflammation and metabolic disorder through inhibition of NLRP3 inflammasome activation. Immunity. 2013 Jun 27;38(6):1154-63.
  63. Tikhonenko M, Lydic TA, Opreanu M, et al. N-3 polyunsaturated Fatty acids prevent diabetic retinopathy by inhibition of retinal vascular damage and enhanced endothelial progenitor cell reparative function. PLoS One. 2013;8(1):e55177.
  64. Maki KC, Reeves MS, Farmer M, et al. Krill oil supplementation increases plasma concentrations of eicosapentaenoic and docosahexaenoic acids in overweight and obese men and women. Nutr Res. 2009 Sep;29(9):609-15.
  65. Tandy S, Chung RW, Wat E, et al. Dietary krill oil supplementation reduces hepatic steatosis, glycemia, and hypercholesterolemia in high-fat-fed mice. J Agric Food Chem. 2009 Oct 14;57(19):9339-45.
  66. Burri L, Berge K, Wibrand K, Berge RK, Barger JL. Differential effects of krill oil and fish oil on the hepatic transcriptome in mice. Front Genet. 2011;2:45.
  67. Ferramosca A, Conte A, Burri L, et al. A krill oil supplemented diet suppresses hepatic steatosis in high-fat fed rats. PLoS One. 2012;7(6):e38797.
  68. Sakaguchi K, Morita I, Murota S. Eicosapentaenoic acid inhibits bone loss due to ovariectomy in rats. Prostaglandins Leukot Essent Fatty Acids. 1994 Feb;50(2):81-4.
  69. Kruger MC, Coetzer H, de Winter R, Gericke G, van Papendorp DH. Calcium, gamma-linolenic acid and eicosapentaenoic acid supplementation in senile osteoporosis. Aging (Milano). 1998 Oct;10(5):385-94.
  70. Salari Sharif P, Asalforoush M, Ameri F, Larijani B, Abdollahi M. The effect of n-3 fatty acids on bone biomarkers in Iranian postmenopausal osteoporotic women: a randomized clinical trial. Age (Dordr). 2010 Jun;32(2):179-86.
  71. Bonnet N, Ferrari SL. Effects of long-term supplementation with omega-3 fatty acids on longitudinal changes in bone mass and microstructure in mice. J Nutr Biochem. 2011 Jul;22(7):665-72.
  72. Fernandes G, Lawrence R, Sun D. Protective role of n-3 lipids and soy protein in osteoporosis. Prostaglandins Leukot Essent Fatty Acids. 2003 Jun;68(6):361-72.
  73. Sun D, Krishnan A, Zaman K, Lawrence R, Bhattacharya A, Fernandes G. Dietary n-3 fatty acids decrease osteoclastogenesis and loss of bone mass in ovariectomized mice. J Bone Miner Res. 2003 Jul;18(7):1206-16.
  74. Bhattacharya A, Rahman M, Banu J, et al. Inhibition of osteoporosis in autoimmune disease prone MRL/Mpj-Fas(lpr) mice by N-3 fatty acids. J Am Coll Nutr. 2005 Jun;24(3):200-9.
  75. Rahman MM, Bhattacharya A, Fernandes G. Docosahexaenoic acid is more potent inhibitor of osteoclast differentiation in RAW 264.7 cells than eicosapentaenoic acid. J Cell Physiol. 2008 Jan;214(1):201-9.
  76. Rahman MM, Bhattacharya A, Banu J, Kang JX, Fernandes G. Endogenous n-3 fatty acids protect ovariectomy induced bone loss by attenuating osteoclastogenesis. J Cell Mol Med. 2009 Aug;13(8b):1833-44.
  77. Li Y, Seifert MF, et al. Dietary conjugated linoleic acids alter serum IGF-I and IGF binding protein concentrations and reduce bone formation in rats fed (n-6) or (n-3) fatty acids. J Bone Miner Res. 1999 Jul;14(7):1153-62.
  78. Baker KR, Matthan NR, Lichtenstein AH, et al. Association of plasma n-6 and n-3 polyunsaturated fatty acids with synovitis in the knee: the MOST study. Osteoarthritis Cartilage. 2012 May;20(5):382-7.
  79. Gruenwald J, Petzold E, Busch R, Petzold HP, Graubaum HJ. Effect of glucosamine sulfate with or without omega-3 fatty acids in patients with osteoarthritis. Adv Ther. 2009 Sep;26(9):858-71.
  80. Hutchins-Wiese HL, Kleppinger A, Annis K, et al. The impact of supplemental n-3 long chain polyunsaturated fatty acids and dietary antioxidants on physical performance in postmenopausal women. J Nutr Health Aging. 2013 Jan;17(1):76-80.
  81. Wann AK, Mistry J, Blain EJ, Michael-Titus AT, Knight MM. Eicosapentaenoic acid and docosahexaenoic acid reduce interleukin-1beta-mediated cartilage degradation. Arthritis Res Ther. 2010;12(6):R207.
  82. Knott L, Avery NC, Hollander AP, Tarlton JF. Regulation of osteoarthritis by omega-3 (n-3) polyunsaturated fatty acids in a naturally occurring model of disease. Osteoarthritis Cartilage. 2011 Sep;19(9):1150-7.
  83. Corbee RJ, Barnier MM, van de Lest CH, Hazewinkel HA. The effect of dietary long-chain omega-3 fatty acid supplementation on owner’s perception of behaviour and locomotion in cats with naturally occurring osteoarthritis. J Anim Physiol Anim Nutr (Berl). 2012 Aug 11.
  84. Moreau M, Troncy E, Del Castillo JR, Bedard C, Gauvin D, Lussier B. Effects of feeding a high omega-3 fatty acids diet in dogs with naturally occurring osteoarthritis. J Anim Physiol Anim Nutr (Berl). 2012 Jul 14.
  85. Ierna M, Kerr A, Scales H, Berge K, Griinari M. Supplementation of diet with krill oil protects against experimental rheumatoid arthritis. BMC Musculoskelet Disord. 2010;11:136.
  86. Deutsch L. Evaluation of the effect of Neptune Krill Oil on chronic inflammation and arthritic symptoms. J Am Coll Nutr. 2007 Feb;26(1):39-48.
  87. Holub BJ. Clinical nutrition: 4. Omega-3 fatty acids in cardiovascular care. CMAJ. 2002 Mar 5;166(5):608-15.
  88. Angerer P, von Schacky C. n-3 polyunsaturated fatty acids and the cardiovascular system. Curr Opin Lipidol. 2000 Feb;11(1):57-63.
  89. Schmidt EB, Skou HA, Christensen JH, Dyerberg J. N-3 fatty acids from fish and coronary artery disease: implications for public health. Public Health Nutr. 2000 Mar;3(1):91-8.
  90. Marik PE, Varon J. Omega-3 dietary supplements and the risk of cardiovascular events: a systematic review. Clin Cardiol. 2009 Jul;32(7):365-72.
  91. Pauwels EK, Kostkiewicz M. Fatty acid facts, Part III: Cardiovascular disease, or, a fish diet is not fishy. Drug News Perspect. 2008 Dec;21(10):552-61.
  92. Pittet YK, Berger MM, Pluess TT, Voirol P, Revelly JP, Tappy L, Chioléro RL. Blunting the response to endotoxin in healthy subjects: effects of various doses of intravenous fish oil. Intensive Care Med. 2010 Feb;36(2):289-95.
  93. Dewailly E, Blanchet C, Gingras S, Lemieux S, Holub BJ. Fish consumption and blood lipids in three ethnic groups of Quebec (Canada). Lipids. 2003 Apr;38(4):359-65.
  94. Albert CM, Campos H, Stampfer MJ, et al. Blood levels of long-chain n-3 fatty acids and the risk of sudden death. N Engl J Med. 2002 Apr 11;346(15):1113-8.
  95. Harris WS, Von Schacky C. The Omega-3 Index: a new risk factor for death from coronary heart disease? Prev Med. 2004 Jul;39(1):212-20.111
  96. von Schacky C, Harris WS. Cardiovascular benefits of omega-3 fatty acids. Cardiovasc Res. 2007 Jan 15;73(2):310-5.
  97. Lemaitre RN, King IB, Mozaffarian D, Kuller LH, Tracy RP, Siscovick DS. n-3. Polyunsaturated fatty acids, fatal ischemic heart disease, and nonfatal myocardial infarction in older adults: the Cardiovascular Health Study. Am J Clin Nutr. 2003 Feb;77(2):319-25.
  98. Zong G, Ye X, et al. Associations of erythrocyte palmitoleic acid with adipokines, inflammatory markers, and the metabolic syndrome in middle-aged and older Chinese. Am J Clin Nutr. 2012 Nov;96(5):970-6.
  99. Kurotani K, Sato M, et al. High levels of stearic acid, palmitoleic acid, and dihomo-linolenic acid and low levels of linoleic acid in serum cholesterol ester are associated with high insulin resistance. Nutr Res. 2012 Sep;32(9):669-675.e3.